Scilex Holding Company (SCLXW) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Scilex Holding Company
Address
960 San Antonio Road
Palo Alto, CA 94303
United States of America (the)
Phone
650 516 4310
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
115
First IPO Date
March 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Henry H. Ji | Chief Executive Officer, President & Executive Chairman | 1.58M | 1964 |
| Suresh K. Khemani | Senior Vice President, Chief Commercial Officer & GM of Scilex Pharma | 456,820 | 1960 |
| Dmitri V. Lissin | Senior Vice President of Clinical Development and Medical Affairs & Interim Chief Medical Officer | 528,826 | 1959 |
| Stephen Ma | Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary & Director | 718,783 | 1973 |
| Suketu D. Desai | Interim Chief Technical Officer & Senior Vice President | 0 | 1966 |
| Gigi DeGuzman | Vice President & Chief People Officer | 0 | N/A |
Description
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
